LoginSubscribe Now
International In-house Counsel Journal Logo
International In-house Counsel Journal Logo
  • Home
  • Business Sectors
  • Areas of Law
  • Editorial Board
  • Write a Paper
  • Subscribe
  • Books
  • Reports
  • Back Issues
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • PLS LogoCopyright & permissions
© 2026 International In-house Counsel Journal Ltd. | ISSN 1754-0607 | Picture Credits: Freepix, Unsplash and by permission of the authors
Back to library search

Managing Compliance Risk in a COVID and Post-COVID World

November 2020ManagementPharmaceutical

Abstract

Managing risk can be complicated in the best of times, and the challenges associated with risk management become even greater when combined with the tremendous disruption caused by a global pandemic. In 2020, the world was hit by a global coronavirus disease (COVID-19) pandemic. This pandemic has created many challenges for governments, businesses, and individuals, and created new risk considerations for companies relating to workplace health and safety, privacy, security, employee oversight, and general health and wellness. In managing these new risk considerations associated with the pandemic and ensuring preparedness for future calamitous and yet unforeseen events, companies need to ensure that their own policies and processes relating to crisis management are updated to reflect our new reality. As part of this planning process, companies should consider contingency plans for various potential disasters, both natural and man-made. These plans should include a clear communication strategy, as well as guidance to employees on what actions to take in such situations. With proper planning and preparation, companies will be ready to mitigate the damage that will inevitably come with the next unexpected crisis.

Subscribe to reador
PLS Logo Copyright & permissions

Authors

Brenda Crabtree

Director, Compliance Auditing and Monitoring, Aimmune Therapeutics, USA

Laura Hamm

Sr. Director, Corporate Compliance, Aimmune Therapeutics, USA

Fabiana Lacerca-Allen

Chief Compliance Officer, Cipla, USA

Tatiyana Akers

Associate Director, Compliance, Aimmune Therapeutics, USA

Related Papers

Paper Title International Pharma Congresses during Covid-19
Pharmaceutical congresses and conferences are one of the preferred resources for doctors to learn about new research, treatments and indications . Such congresses in 2020 have become ‘virtual’ in response...Read more
Portrait image of Geraldine Benjamin
Geraldine Benjamin
English Solicitor, Bailhache Labesse Trustees, UK
Making it Stick: How to Provide Legal Advice that Influences Business Decisions
As attorneys, determining the most risk-averse legal advice to give to our business partners often comes naturally. After all, we have both academic and professional experience in considering legal questions. But...Read more
Portrait image of Joshua Axelrod
Joshua Axelrod
Brand Counsel, Celgene Corporation, Ireland
Client Centricity & the In-House Lawyer
The practice of law has evolved, particularly given the advent of significant technological advances, enhancements, and the evolving nature of the business world. Twenty years ago, first year law students’...Read more
Portrait image of Kari Loeser
Kari Loeser
Senior Counsel, Jazz Pharmaceuticals, USA
A Glance at Some of the Challenges of the GC Role in Pharma
In the heavily regulated environment in which pharmaceutical companies operate, success is defined by ensuring corporate compliance with disparate laws and regulations without fettering the creativity and innovation on which...Read more
Portrait image of Galit Gonen
Galit Gonen
Senior Vice President & General Counsel for Teva Europe, Teva Pharmaceuticals, UK